Skip to Main Content

Paper Details

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Science Signaling
36
2019
3D cell cultures, CDK9, KRAS, KRAS-mutant, KRAS-mutant PDAC cell line, KRAS-mutant pancreatic cancer, MYC, MYC oncoprotein, MYC protein, PDAC, Ser62, UNC10112785, pancreatic ductal adenocarcinoma, patients
Author NameAffiliation
Laura E HerringUniversity of North Carolina at Chapel Hill
Laura E HerringUniversity of North Carolina at Chapel Hill
  • 1 - 2

Datasets

Release 1.2